beta

CNAT

Conatus Pharmaceuticals, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Market Cap: 18.6 Million

Primary Exchange: NASDAQ

Website: http://www.conatuspharma.com

Shares Outstanding: 33.2 Million

Float: 32.2 Million

Dividend: (%)

Beta: 0.8780833253905082

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 1623 trading days

From: 2014-01-10 To: 2020-05-26

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud